In a recent ruling by the Federal Circuit, it was held that Meril Life Sciences is protected under a patent safe harbor when presenting its preapproval transcatheter heart valve system at an industry conference. This decision comes amid claims from Edwards Lifesciences, which Meril argues are merely delay tactics aimed at stalling their progress. The full details of this legal dispute and the court’s rationale can be accessed here.